ClinicalTrials.gg
CompletedNCT07791524Updated Aug 28, 2026

Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity

A Phase 2 interventional study of MWN109 1 and MWN109 2 in Overweight , Obesity, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2026, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Obesity by Lepu Medical — 6 open to participants now, 8 under way, 1 of them phase 3. Obesity · Lepu Medical.

Enrollment
2nd of 14
255 · median 88
Started
2026
with 6 others
Phase 2
5 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Obesity by Lepu Medical, this one is the 2nd largest by enrollment, is one of 7 that started in 2026, is one of 5 in phase 2, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 14 studies in Obesity by Lepu Medical are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Obesity by Lepu Medical, or all of them as a file.
02

Study summary

This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants with overweight or obesity.

Approximately 240 participants will be enrolled. All participants will be stratified by gender (male or female) and then randomized 1:1:1:1:1 to 5 treatment groups, with approximately 48 participants per group. All treatment groups will implement dose titration to achieve the target dose.

This study consists of a screening period of up to 2 weeks, a treatment period of 20 weeks, and a follow-up period of 2 weeks, totaling 24 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 20 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 20 weeks of treatment, as well as the change in waist circumference relative to the baseline.

03

Conditions studied

  • Overweight , Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 255 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female individuals aged 18 to 65 years (inclusive), as determined by the date of signing the form;
  2. Weight ≥ 70 kg (for males) or ≥ 60 kg (for females), with a (BMI) ≥ 30 kg/m² (obesity), or 27 kg/m² ≤ BMI \< 30 kg/m² (overweight) and at least one weight-related comorbidity (such as hypertension, dyslipidemia, prediabetes, obstructive sleep apnea syndrome, metabolic dysfunction-associated steatotic liver disease, weight-bearing joint pain, cardiovascular diseases, polycystic ovary syndrome, etc.);
  3. Resting heart rate ≥ 55 and ≤ 90 beats per minute (based on 12-lead results during screening and before randomization);
  4. The subject has undertaken weight management via diet and exercise alone for at least 12 weeks prior to screening, with a weight change of \<5.0% (self-reported), and is able to continue the same diet-and-exercise-based weight management during the study period.
  5. Participants must have no pregnancy plans from the time of signing informed consent until 3 months after the last dose of the product, must use effective to avoid pregnancy or partner pregnancy, and must have no plans to donate sperm or eggs.

Exclusion criteria

Exclusion Criteria:

  1. It is known that the subject has an allergic constitution, or is allergic to any component of glucagon-like peptide-1 (GLP-1) receptor agonist drugs or medicinal products, or has a severe allergic disease during screening, or has a history of severe drug allergy in the past;
  2. Use of any anti-hyperglycemic agents, weight-affecting medications, or prescription weight-loss medications for weight control within 12 weeks prior to screening; over-the-counter weight-loss medications or appetite suppressants within 4 weeks;
  3. Laboratory abnormalities: or AST ≥ 3×; total ≥ 1.5×ULN; \< 60 mL/min/1.73m²; \< 110 g/L (males) or \< 100 g/L (females); serum calcitonin ≥ 35 ng/L; TSH > 6.0 or \< 0.4 mIU/L; fasting triglycerides ≥ 5.64 mmol/L; serum amylase or lipase > 2.0×ULN;
  4. It is known or discovered during screening that the is abnormal and there is a significant safety risk, or further diagnosis and treatment are required, including but not limited to: arrhythmias that cannot be controlled or require drug treatment such as persistent ventricular tachycardia, second or third degree atrioventricular block, > 450 ms, long QT syndrome family history or Brugada syndrome family history, etc.
  5. There is a history or evidence of any of the following diseases: secondary or drug-induced overweight or obesity; previous diagnosis of type 1 or type 2 diabetes, or at least one laboratory test indicator suggesting diabetes during screening; previous diagnosis of acute or chronic pancreatitis, or pancreatic injury; history of gallstones or cholecystitis during screening; previous diagnosis of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2A or 2B, or a related family history; previously undergone gastric weight loss surgery or other weight loss surgeries, or plans to undergo weight loss surgery, liposuction, abdominal lipolysis, or other surgeries that significantly affect body weight during the study period; previously had moderate or severe depression; diagnosed with a malignant tumor within the previous 5 years or evaluated as having potential malignant tumors during screening; history of any heart disease within 6 months before screening or before randomization; cerebrovascular accident within 6 months before screening or before randomization; uncontrolled hypertension during the screening period; history of hyperthyroidism or hypothyroidism, or abnormal thyroid function test results during screening; clinically significant gastric emptying abnormalities, requires long-term use of drugs that directly affect gastrointestinal motility, or active gastrointestinal diseases during screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    MWN109 Cohort 1

    Drug: MWN109 1

  • Experimental
    MWN109 Cohort 2

    Drug: MWN109 2

  • Experimental
    MWN109 Cohort 3

    Drug: MWN109 3

  • Experimental
    MWN109 Cohort 4

    Drug: MWN109 4

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered orally, QD, 20 weeks

  • Administered orally, QD, 20 weeks

  • Administered orally, QD, 20 weeks

  • Administered orally, QD, 20 weeks

  • DrugPlacebo

    Administered orally, QD, 20 weeks

07

What researchers measure

Primary outcomes

  1. Percentage change in body weight compared to baseline after 20 weeks of drug administration

    Percentage change in body weight from baseline to Week 20.

    Time frame: Baseline, week 20

Secondary outcomes

  1. Change from baseline in body weight over time

    Change in body weight from baseline to week 20.

    Time frame: Baseline, week 20

  2. Proportion of Participants Achieving ≥5% Body Weight Reduction from Baseline at week 20

    Proportion of participants with a body weight reduction of 5% or more from baseline at week 20.

    Time frame: Baseline, week 20

  3. Proportion of Participants Achieving ≥10% Body Weight Reduction from Baseline at week 20

    Proportion of participants with a body weight reduction of 10% or more from baseline at week 20.

    Time frame: Baseline, week 20

  4. Proportion of Participants Achieving ≥15% Body Weight Reduction from Baseline at week 20

    Proportion of participants with a body weight reduction of 15% or more from baseline at week 20.

    Time frame: Baseline, week 20

  5. Proportion of Participants Achieving ≥20% Body Weight Reduction from Baseline at week 20

    Proportion of participants with a body weight reduction of 20% or more from baseline at week 20.

    Time frame: Baseline, week 20

  6. Change from baseline in waist circumference over time

    Change in waist circumference from baseline to week 20.

    Time frame: up to 20 weeks

  7. Change from baseline in body mass index (BMI) over time

    Change in BMI from baseline throughout the study.

    Time frame: up to 20 weeks

  8. Change from baseline in lipid profile over time

    Change in lipid parameters (including total cholesterol, LDL-C, HDL-C, triglycerides) from baseline throughout the study.

    Time frame: up to 20 weeks

  9. Change from baseline in blood pressure over time

    Change in systolic and diastolic blood pressure from baseline throughout the study.

    Time frame: up to 20 weeks

  10. Change from baseline in fasting insulin over time

    Change in fasting serum insulin levels from baseline throughout the study.

    Time frame: up to 20 weeks

  11. Change from baseline in fasting plasma glucose (FPG) over time

    Change in fasting plasma glucose levels from baseline throughout the study.

    Time frame: up to 20 weeks

  12. Change from baseline in glycated hemoglobin (HbA1c) over time

    Change in HbA1c levels from baseline throughout the study.

    Time frame: up to 20 weeks

  13. Change from baseline in serum uric acid over time

    Change in serum uric acid levels from baseline throughout the study.

    Time frame: up to 20 weeks

  14. Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Score over time

    Change in IWQOL-Lite-CT score from baseline throughout the study. The IWQOL-Lite-CT, a 20-item patient-reported outcome (PRO) tool, evaluates weight-related physical and psychosocial function. Each of its 5 response choices (A-E) yields a score from 1 to 5. Total scores range from 20 to 100. Higher composite and total scores are associated with better participant-reported functioning.

    Time frame: up to 20 weeks

  15. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number and proportion of participants with treatment-emergent adverse events throughout the study.

    Time frame: up to 20 weeks]

08

Study locations

1 site
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jul 2026, 6 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 6 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 28, 2026
StartActual
Jan 5, 2026
Primary completionActual
Jul 9, 2026
CompletionActual
Jul 9, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07791524
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Jan 5, 2026
Primary completion
Jul 9, 2026
Completion
Jul 9, 2026
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MWN109

Start the discussion